This Integrative Pharmacological Sciences Training Program (IPSTP) is designed to support 2nd and 3rd year Ph.D. students pursuing dissertation research projects in the pharmacological sciences. Trainees and training faculty are drawn from 7 Ph.D. programs (Biochemistry & Molecular Biology, Chemistry, Chemical Engineering and Materials Science, Microbiology & Molecular Genetics, Neuroscience, Pharmacology & Toxicology and Physiology). The two areas of unique focus within the IPSTP are training on in vivo pharmacological approaches and drug discovery. The research expertise of IPSTP training faculty is clustered into three overlapping themes: 1) the intersection of molecular mechanisms of disease with novel therapeutic design; 2) integration of endocrine and metabolic derangements with cancer and cardiovascular processes; and, 3) application of systems biology and bioinformatics to understand drug mechanisms and disease. Funds are requested to support 8 students (or 4 students entering the program per year). The training program will be administered by a Program Director (Neubig), two Associate Directors (Dorrance and Atchison) and an Executive Committee composed of representatives from the programs. The program is also guided by an External Advisory Committee of experts from Pharmacology Ph.D. programs and the pharmaceutical industry and a Student Advisory Committee composed of trainees. There are 8 core elements to the training plan: 1) a research project whose results lead to a Ph.D. dissertation and a contribution to knowledge in the pharmacological sciences; 2) two week-long intensive courses in drug discovery and in vivo pharmacology; 3) a three course curriculum in pharmacology and biostatistics; 4) a two course curriculum in professional development; 5) participation in a quantitative systems biology workshop; 6) a monthly Communications Skills and Professional Development Forum; 7) participation in an annual program retreat; 8) a monthly student-run journal club. Students will be expected to participate in the last three elements for the duration of their direct T32 support and for all subsequent years until graduation. Trainees are also required to attend the Responsible Conduct of Research (RCR) workshop series provided by the Graduate School and program specific RCR activities. Supplemental activities available to trainees include: 1) teaching opportunities; 2) participation in the NIH-funded MSU BEST program, and 3) field-trips to regional sites for non-academic careers. The IPSTP has developed a comprehensive plan to recruit highly qualified students including under- represented minority students. The IPSTP will provide trainees with excellent research and professional training and will prepare them for research careers in academia, industry and government.

Public Health Relevance

The proposed training program will prepare students to be leaders in the field of pharmacological sciences. IPSTP trainees will receive in-depth training in the science of drug discovery and in vivo pharmacology, and trainees completing this program will make important contributions to our understanding of the causes and treatments of human illness. Students will graduate from the program prepared for a range of scientific careers in academia, industry, and government.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM092715-09
Application #
9717247
Study Section
NIGMS Initial Review Group (TWD)
Program Officer
Koduri, Sailaja
Project Start
2011-07-01
Project End
2021-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Michigan State University
Department
Pharmacology
Type
Schools of Osteopathic Medicine
DUNS #
193247145
City
East Lansing
State
MI
Country
United States
Zip Code
48824
Zagorski, Joseph W; Turley, Alexandra E; Freeborn, Robert A et al. (2018) Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T cell activation. Biochem Pharmacol 147:67-76
Zhang, Di; Leal, Ana S; Carapellucci, Sarah et al. (2018) Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762. Cancer Prev Res (Phila) 11:143-156
Fader, Kelly A; Nault, Rance; Raehtz, Sandi et al. (2018) 2,3,7,8-Tetrachlorodibenzo-p-dioxin dose-dependently increases bone mass and decreases marrow adiposity in juvenile mice. Toxicol Appl Pharmacol 348:85-98
Fader, K A; Nault, R; Kirby, M P et al. (2018) Corrigendum to ""Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERB?/? activation in aryl hydrocarbon receptor-elicited hepatotoxicity"" [Toxicol. Appl. Pharmacol. 321 (2017) 1-17]. Toxicol Appl Pharmacol 344:74
Woodworth, Hillary L; Perez-Bonilla, Patricia A; Beekly, Bethany G et al. (2018) Identification of Neurotensin Receptor Expressing Cells in the Ventral Tegmental Area across the Lifespan. eNeuro 5:
Mohammadiarani, Hossein; Shaw, Vincent S; Neubig, Richard R et al. (2018) Interpreting Hydrogen-Deuterium Exchange Events in Proteins Using Atomistic Simulations: Case Studies on Regulators of G-Protein Signaling Proteins. J Phys Chem B 122:9314-9323
Phillips, Aaron A; Matin, Nusrat; Jia, Mengyao et al. (2018) Transient Hypertension after Spinal Cord Injury Leads to Cerebrovascular Endothelial Dysfunction and Fibrosis. J Neurotrauma 35:573-581
Diaz-Otero, Janice Marie; Yen, Ting-Chieh; Fisher, Courtney et al. (2018) Mineralocorticoid Receptor Antagonism Improves Parenchymal Arteriole Dilation Via a TRPV4-Dependent Mechanism and Prevents Cognitive Dysfunction in Hypertension. Am J Physiol Heart Circ Physiol :
Nault, Rance; Doskey, Claire M; Fader, Kelly A et al. (2018) Comparison of Hepatic NRF2 and Aryl Hydrocarbon Receptor Binding in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Treated Mice Demonstrates NRF2-Independent PKM2 Induction. Mol Pharmacol 94:876-884
Zhang, Di; Rennhack, Jonathan; Andrechek, Eran R et al. (2018) Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Antioxid Redox Signal 29:1535-1552

Showing the most recent 10 out of 56 publications